Transcription of the telokin gene is restricted to smooth muscle cells throughout development, making this gene an excellent model for unraveling the mechanisms that regulate gene expression in smooth muscle tissues. To identify proteins that bind to the telokin promoter, the AT-rich/CArG core of the promoter was used as a probe to perform a Southwestern screen of a mouse bladder cDNA library. Four clones corresponding to 2 distinct isoforms of mouse thyrotroph embryonic factor (TEFα and TEFβ) were identified from this screen. The two TEF isoforms differ from each other at their amino termini and result from alternative promoter usage. RNase protection assay showed that both TEF isoforms are expressed at high levels in mouse lung, bladder, kidney, gut and brain. Gel mobility shift assays demonstrated that purified TEF protein can specifically bind to an AT-rich region within the core of the telokin promoter. Furthermore, when over-expressed in 10T1/2 cells, TEF significantly increased the activity of a telokin promoter-reporter gene, this activation was further augmented by elevated intracellular calcium levels. In contrast, over-expression of TEF had no effect on reporter genes driven by SM22α, smooth muscle α-actin or smooth muscle myosin heavy chain 
INTRODUCTION
There is extensive evidence showing that altered control of the differentiated state of smooth muscle cells contributes to the development and/or progression of a variety of diseases including atherosclerosis, hypertension and asthma. These diseases are all associated with decreased expression of proteins required for the differentiated function of the smooth muscle cells. An understanding of the mechanisms that control smooth muscle cell differentiation is required before it will be possible to determine how these control processes are altered in pathological conditions.
To begin to elucidate the molecular mechanisms that control smooth muscle cell differentiation we have sought to determine which transcription factors are important for regulating expression of the telokin gene in smooth muscle tissues. Telokin is a smooth muscle-restricted protein with an amino acid sequence that is identical to the carboxylterminal domain of myosin light chain kinase (MLCK) (1) . Although the physiological function of telokin has not been fully elucidated, previous studies have suggested that telokin may play a role in regulating smooth muscle contractility. Telokin has been shown to stabilize unphosphorylated myosin filaments in vitro (2, 3) . Telokin has also been shown to accelerate the dephosphorylation of myosin light chain and induce relaxation of permeabilized smooth muscle strips, through activation of myosin light chain phosphatase (4) .
Transcription of telokin is strictly restricted to smooth muscle cells throughout mouse development, which makes this gene a good marker for studying the control of smooth muscle cell lineage (5) . Telokin mRNA is transcribed from an internal promoter, located within an intron, in the 3' region of the MLCK gene (6) . In vitro reporter gene assays have shown that 310bp (-163 to +147) and 370bp (-190 to +180) fragments of the rabbit and mouse telokin promoters, respectively, are sufficient to mediate cell-specific expression (6, 7) . Both of these telokin promoters are also sufficient to direct transgene expression specifically to smooth muscle tissues in adult mice (7, 8) . Transgenes driven by these promoters are expressed at much higher levels in visceral as opposed to vascular smooth muscle tissues. Several positive-acting elements, within the minimal telokin promoter, including an E box, AT-rich region, and CArG-box were shown to be important for reporter gene activity in A10 smooth muscle cells (9) . A core fragment of the minimal telokin promoter including the E box, AT-rich region and CArG box has been shown to specifically increase expression of the normally vascular smooth musclespecific SM22α promoter in smooth muscle cells of the bladder (7) . The AT-rich region acting together with the CArG box appears to be important for determining cellspecificity, as these combined elements increase the activity of a minimal thymidine kinase promoter in A10 smooth muscle cells but not in fibroblasts. In contrast, the ATrich element alone had no effect on thymidine kinase promoter activity and the CArG element increased activity of the promoter in both fibroblasts and smooth muscle cells (7) .
The CArG element in the telokin promoter has been shown to bind to serum response factor (SRF) (9) . Many smooth muscle-specific genes require critical evolutionarily conserved CArG boxes that bind SRF for their expression in smooth muscle cells in vitro and in transgenic mice (10) . Recent studies have demonstrated that the interaction of SRF with the co-activator myocardin is a critical determinant of smooth muscle development (11) . Although interaction of SRF with myocardin is clearly critical for activating most smooth muscle restricted genes, neither myocardin nor SRF are expressed only in smooth muscle cells, hence additional regulatory proteins must be required to restrict gene expression to smooth muscle cells.
A number of studies have suggested that AT-rich regions are involved in the regulation of expression of smooth muscle-restricted genes. Modulator recognition factor 2 (Mrf2), a member of the AT-rich interaction domain family of transcription factors, has been shown to induce the pluripotent neural crest cell line (MONC-1) to differentiate into smooth muscle cells (12) . We previously identified a transcription factor of the forkhead family, Foxq1 (hepatocyte nuclear factor-3 homologue 1) that binds to the AT-rich region of the telokin promoter and strongly represses telokin promoter activity when over-expressed in A10 vascular smooth muscle cells (13) . In the current study we employed a lambda Southwestern screen of a mouse bladder cDNA library, using the AT-rich/CArG core of the telokin promoter as a probe, in order to identify additional proteins that can bind to this region of the promoter. Four clones corresponding to 2 distinct isoforms of mouse thyrotroph enhancer factor (TEF), were identified (14) . The two TEF isoforms differ from each other at their amino termini and arise from alternative promoter usage. Gel mobility shift assays confirmed that purified TEF protein specifically bound to the AT-rich region (TTATATAA) within the core of the telokin promoter. Furthermore, TEF can significantly increase telokin promoter-reporter gene activity in 10T1/2 cells in a calcium dependent manner. No activation of other smooth muscle promoters such as SM22α, smooth muscle α-actin (SM α-actin) and smooth muscle myosin heavy chain (smMHC) was observed. Over-expression TEFα and TEFβ in A10 cells up-regulated expression of endogenous telokin but not SM22α, SM α-actin and smMHC expression. These data suggest that TEF may play an important role in the activation of telokin expression in smooth muscle tissues. 
METHODS

Lambda Southwestern Screen
A mouse bladder cDNA library in lambda gt11, described previously (13) was screened to identify LAC-cDNA encoded fusion proteins that were capable of binding to the ATrich/CArG core of the telokin promoter. E. coli Y1090r-were infected with the lambda gt11 cDNA library phage and plated on 150mm dishes using standard procedures (15).
Plates were overlayed with nitrocellulose filters soaked in 10mM IPTG, to induce expression of LAC fusion proteins. After 6 hours the filters were removed, blocked by incubation in BLOTTO (5% nonfat milk powder, 50mM Tris.Cl, pH7.5, 50mM NaCl, 1mM EDTA, 1mM DTT) for 1 hour at room temperature. Filters were then washed three times in binding buffer (10mM Tris pH7.5, 50mM NaCl, 1mM EDTA, 1mM DTT) and stored overnight at 4°C. Filters were incubated with probes at a concentration of 10 6 cpm/ml in binding buffer for 1 hour at room temperature, unbound probe was then removed by 4x7.5 minute washes with binding buffer. Positive clones were then identified by autoradiography. The probe used for this screen comprised three tandem copies of the core of the mouse telokin promoter (-90 to -53) as described previously (13) . This fragment was generated by ligating double-stranded oligonucleotides into EcoR1 linearized pGEM7Z (Promega, Madison WI) the sequence of these oligonucleotides were; Sense 5'-aattctgcagttgctttatataaactatcccttttatggg agc-3'; antisense 5'-aattgctcccataaaagggatagtttatataaagcaactgcag-3'. The sequence and orientation of the fragments was confirmed by direct DNA sequencing. The trimerized fragment was isolated by digestion with Xho I and Bam HI, separated by agarose gel electrophoresis and purified using Qiaex II beads (Qiagen, Valencia, CA). This fragment was then endlabeled using the Klenow fragment of DNA polymerase and 32 P-dCTP and unincorporated nucleotide removed by spin column chromatography (Biorad, Hercules, CA). Approximately 1x10 6 plaques were screened from the library, positive plaques were picked and rescreened until clonal. DNA was prepared from positive plaques using lamdabsorb according to the manufactures directions (Promega, Madison, WI). cDNAs were then subcloned into pGEM5Z subjected to direct automated DNA sequencing (Seqwright, Houston, TX).
RNase Protection Assays
Total RNA was isolated from tissues and cells using guanidinium isothiocyanate (15). A 260bp fragment of the TEFβ cDNA (corresponding to nucleotides 1-260) was subcloned into pGEM7Z (Promega, Madison WI). The plasmid was linearized with Sal I and a 32 Plabeled antisense riboprobe (300bp) generated using SP6 polymerase and a Maxi Script in vitro Transcription kit according to the manufacturer's directions (Ambion, Austin, TX). The TEF riboprobe was gel purified on a 6% polyacrylamide/ 8M urea gel and eluted overnight at 37°C. Ribonuclease protection assays were then performed according to the manufacturer's directions (Standard RPA II kit, Ambion). Briefly, 1X10 5 cpm of gel purified TEF riboprobe was co-precipitated with 20 µg RNA and hybridized overnight at 42°C. Samples were digested with RNase A/T1 at 1:100 dilution for 30 min.
at 37°C and then inactivated and precipitated. Samples were solubilized in 8µl gel loading buffer and one half the volume was loaded onto a 6% polyacrylamide/8M urea gel run at 55W for 2 hours. Riboprobes of known sizes were run alongside RPA samples to verify the size of the probe and protected fragments. The riboprobe used will protect a 260bp fragment of mouse TEFβ but only a 131bp fragment of TEFα. 
Gel mobility shift analysis of DNA binding
Expression of Recombinant proteins in bacteria.
Full-length human SRF, mouse TEFα and TEF-DN were expressed in bacteria using the pET expression system (Novagen, EMD biosciences San Diego, CA). SRF and TEFα were purified as described previously (13) . TEF-DN was used as an unpurified bacterial lysate.
Mammalian expression and reporter gene assays
For expression in mammalian cells TEF cDNAs were cloned into pcDNA 3.1 HisC to +11,600 (19) . The minimal TK promoter used comprised nucleotides -113 to +20 of the thymidine kinase gene. Point mutations in the rabbit telokin promoter were generated as described previously (9 Luciferase Assay System essentially as described by the manufacturer (Promega, Madison, WI). A minimum of six independent transfections was performed and all assays were replicated at least twice. Results are reported as the mean ± S.E. All variables were analyzed by t test and significance was set at pd0.05. For verification of expression of wild type TEF and dominant negative mutant TEF protein, 24 hours after transfection COS cell lysates were generated using RIPA buffer (1% NP40, 1% sodium deoxycholate, 0.1%SDS, 0.15M NaCl, 2mM EDTA, 0.01M sodium phosphate pH7.2) containing protease inhibitors and analyzed by western blotting as described below.
Adenovirus Construction And Cell Infection
Adenovirus constructs were made using the adeno-X vectors obtained from Clontech These cells were washed with PBS to remove serum and infected with adenovirus encoding LacZ, TEF or TEF-DN in PBS at a multiplicity of infection of 100 for 4 h at 37 0 C. These conditions resulted in close to 100% infection of cells. 72 hours following infection cell protein extracts were prepared using RIPA buffer and protein concentrations were determined using the BCA Protein Assay Kit (Pierce Chemical, Rockford, IL).
Western Blotting
Western blotting analysis was carried out essentially as described previously (20) . Fifteen micrograms of protein were fractionated on a 7.5% or 15% SDS-polyacrylamide gels.
The protein sample was electrophoretically transferred to a PVDF membrane and verified 
RESULTS
Identification of Thyrotroph embryonic factor as a telokin AT/CArG binding protein.
Previously we have shown that the CArG box in the telokin promoter together with an adjacent AT-rich region are important for smooth muscle cell-selective expression of a reporter gene in vitro and in vivo (7) . When this fragment was added to an arterial smooth muscle selective SM22α transgene reporter gene activity was selectively increased in bladder smooth muscle cells. This region is also very highly conserved across mammalian species suggesting that important regulatory factors are likely to interact with this region. To identify transcription factors that can bind to the AT/CArG region of the telokin promoter a Southwestern screen of a mouse bladder cDNA library was performed.
From this screen 4 cDNAs were isolated that encoded fragments of thyrotroph embryonic factor (TEF, (14)). The cDNAs isolated represent two distinct TEF isoforms homologous to isoforms TEFα/α and TEFβ/α (referred to as VBP in chicken) described previously in protected fragment) (Figure 2 ). This analysis demonstrated that both TEF isoforms are expressed at high levels in mouse lung, bladder, kidney, brain, liver and heart. However, the ratio of TEF isoforms varies in different tissues, for example, lung, kidney and liver have similar expression of both isoforms but TEFα is expressed at higher levels than TEFβ in bladder, uterus, ileum, heart, skeletal muscle and placenta and in 10T1/2 fibroblasts as well as A10 vascular and GI visceral smooth muscle cells.
TEF binds to an AT-rich region of the telokin promoter
To identify the TEF binding site on the telokin promoter, gel mobility shift assays were carried out using probes to either the AT-rich region and CArG box (AT/CArG), to the AT-rich region alone (AT) or to the CArG box alone (CArG) and purified TEFα protein.
Two TEF-DNA complex bands were observed in assays using AT/CArG and AT probes, but not CArG probes. In contrast, SRF formed a mobility shifted complex using the CArG probe demonstrating the integrity of this probe. The two mobility shifted complexes observed using purified TEF are consistent with previous data (14) and perhaps suggest that TEF can bind as a monomer or dimer (Figure 3 Together these data, suggest that TEF directly binds to the sequence TTATATAA in the AT-rich region of the telokin promoter.
TEF specifically activates telokin promoter activity through binding to AT-rich region element.
To determine the function of TEF binding to the telokin promoter we examined TEF's ability to regulate a telokin promoter-reporter gene. The coding sequences of TEFα or TEFβ cDNAs were inserted into a mammalian expression vector and cotransfected into 10T1/2 or A10 cells together with a reporter plasmid consisting of a firefly luciferase gene under the transcriptional control of a 400bp (253 to +147) rabbit telokin proximal promoter region, which includes the AT-rich region and CArG box. Results from this analysis showed that TEFα and TEFβ increased telokin promoter activity 2.0 and 2.7-fold, respectively in 10T1/2 fibroblast cells ( Figure 4A ). In rat smooth muscle A10 cells, TEFα and β, also stimulated promoter activity 1.2 and 1.4 fold, respectively ( Figure 4A ).
The lower levels of stimulation of the telokin promoter by TEF in A10 smooth muscle cells compared to 10T1/2 fibroblasts likely reflects the much higher basal levels of telokin promoter activity in smooth muscle cells as compared to fibroblasts.
To directly correlate TEF binding and activation of the telokin promoter, mutant telokin promoters were generated that contained single base pair mutations that were shown to block TEF binding in gel mobility shift assays (5A-T and 7A-T in Figure 3B ). As predicted, TEF was unable to activate these mutant telokin promoter reporter genes (Figure 4 B) .
TEF activation is promoter specific
To determine if TEF also activated the promoters of other smooth muscle-specific genes we examined its effects on reporter genes driven by the smooth muscle α-actin, SM22α or the smooth muscle MHC promoters. Results from these luciferase assays revealed that only the telokin promoter was significantly activated by TEF ( Figure 5 ).
An amino-terminal truncated form of TEF acts as a dominant negative
To further evaluate the role of TEF in regulating telokin expression, a dominant negative TEF was generated by deleting the amino-terminal transcription activation domain ( Figure 1A ). The TEF-DN was shown to directly bind to the AT-rich region of the telokin promoter in gel mobility shift assays and to compete with the wild type TEFα for TEF, the TEF-DN had no effect on the activity of the other smooth muscle-specific promoters analyzed (data not shown). These data suggest that the amino terminaltruncated TEF acts as a dominant negative by competing with the wild type TEF for binding to the AT-rich region in the telokin promoter.
TEF activation of the telokin promoter is calcium-dependent.
Previous studies demonstrated that TEF activation of the ICER (Inducible cAMP Early
Repressor) gene is increased by elevated intracellular calcium (22) . We therefore, examined the possibility that calcium regulates the TEF activation of the telokin gene.
Thapsigargin, a drug that increases intracellular calcium by inhibiting endoplasmic reticular Ca 2+ -ATPase, was used to treat the 10T1/2 cells co-transfected with TEF and a telokin reporter gene. Results from these experiments revealed that thapsigargen enhances TEF activity up to 11-fold, in a dose dependent manner ( Figure 7 ).
TEF up-regulates endogenous telokin expression
To further examine the role of TEF in regulating telokin expression in vivo, the ability of adenoviral expressed TEF to regulate endogenous smooth muscle protein expression in (21)). TEF was originally identified as a thyrotroph restricted factor that is required to activate the thyroid stimulating hormone (TSHβ) gene (14) . Although described as an anterior pituitary restricted factor during embryonic development, TEF is more widely distributed in adult rats (25) (27); (28) . Using a binding site selection assay, TEF was found to bind preferentially to the consensus sequence 5'-GTTACGTAAT-3', which is identical to the previously determined HLF recognition site (29) . Results from our gel mobility shift analysis suggest that the TEF binding site on the telokin promoter is TTATATAA (Figure 3 ). This sequence is very similar to the core PAR consensus binding site although missing flanking purine and pyrimidine residues at the 5' and 3' ends respectively, and position 7 is an adenine instead of a guanine. These differences suggest that the binding of TEF to the telokin promoter is likely to be of lower affinity than its' binding to a concensus binding site. A similar lower affinity TEF binding site has recently been reported in the Inducible cAMP Early Repressor (ICER) gene (22) . In addition it was shown that TEF activates ICER gene transcription via a Ca 2+ -dependent mechanism that involves CaMK IV. Consistent with these studies, our results also demonstrate that the activation of the telokin promoter by TEF, is augmented by elevated intracellular calcium levels ( Figure 7) . The calcium dependent regulation of a smooth muscle-specific gene is particularly intriguing in light of the observations that stretch and contractility, two processes that lead to elevated intracellular calcium, are able to help establish and maintain the differentiated state of smooth muscle cells (30) . These data suggest a model, in which the beneficial effects of stretch and contractility on smooth muscle differentiation result, in part, from the calcium-dependent activation of transcription factors, such as TEF, that control the expression of smooth muscle differentiation genes.
The two isoforms of mouse TEF, TEFα and TEFβ isolated in the current study are homologous to the previously described chicken VBPα/α and VBPβ/α isoforms respectively (21) . Alignment of the mouse TEF cDNA sequences with the mouse TEF gene and available EST cDNA sequences failed to provide any evidence of mouse TEF isoforms with alternatively expressed carboxyl-termini similar to those described for VBP. The mouse gene structure is however consistent with the TEFα and β isoforms arising from alternative promoter and first exon usage as described from chicken VBP (Figure 1 ). The ability of TEFβ to activate the telokin promoter and endogenous telokin expression appears to be greater than that of TEFα (Figures 4 and 8 TEF, DBP and HLF have all been shown to display circadian expression patterns in mouse liver and kidney, with TEF and DBP being expressed at highest levels at 8pm and at lowest levels at 8am. (25, 32, 33) These observations suggest the possibility that perhaps downstream targets of TEF such as telokin may also be regulated in a circadian pattern.
However, no circadian pattern of telokin protein expression was observed in gut and bladder tissues harvested at 8 hour intervals during a 24 hour period (data not shown).
These findings may not be totally unexpected, as previous studies have demonstrated that the circadian pattern of expression of TEF and DBP is restricted to tissues such as liver and kidney (25) .
The ability of TEF to activate telokin promoter reporter genes but not the other smooth muscle-specific reporter genes examined, together with the selective effects of TEF over-expression on endogenous telokin and SM22α genes, suggests that TEF regulates the activity of some but not all smooth muscle-specific genes. These data imply that in a single tissue, distinct transcription factors may be involved in the regulation of expression of distinct groups of smooth muscle-specific genes.
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AT/CArG probes containing mutations 5A-T or 7A-T or a wild type probe (WT) were used as probes for gel mobility shift assays. Probes were incubated with either purified TEFα or SRF, as indicated. SRF produced a mobility-shifted complex with each of the probes whereas TEF was only able to bind to the wild type probe. 
